Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies - PubMed
5 days ago
- #Atherosclerosis
- #Residual Risk
- #Statin Therapy
- Residual risk in atherosclerotic cardiovascular disease (ASCVD) persists even with statin therapy and controlled LDL-C levels.
- Non-HDL cholesterol and apolipoprotein B are superior to LDL-C in assessing residual risk.
- Lipoprotein(a) remains predictive of cardiovascular events despite well-controlled LDL-C levels.
- Elevated triglycerides and triglyceride-rich lipoproteins are consistently associated with higher cardiovascular risk.
- Inflammatory biomarkers like high-sensitivity C-reactive protein and interleukin-6 indicate residual inflammatory risk.
- Therapeutic strategies include lifestyle modifications, lipid-lowering agents, anti-inflammatory therapies, and novel gene-silencing approaches.
- Integrated, multi-target strategies are needed for comprehensive cardiovascular protection beyond LDL-C control.